Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The RAS testing in real world management of metastatic colorectal cancer: The results of Italian Laboratories Survey.

Critical reviews in oncology/hematology - 1 May 2026

Pinto Carmine, Malapelle Umberto, Fassan Matteo, Maiello Evaristo, Martinelli Erika, Sartore-Bianchi Andrea, Annibali Viviana, Marchetti Antonio, Normanno Nicola

Abstract excerpt

Approximately 15-30 % of patients with colorectal cancer (CRC) present with metastases at diagnosis, while up to 50 % will develop metastases during follow-up. The integration of targeted drugs into standard chemotherapy has significantly improved clinical outcomes, with anti-EGFR monoclonal antibodies playing a crucial role in the treatment of RAS wild-type metastatic CRC. In this context, high-quality RAS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to EGFR gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Neoplasm Metastasis

Share to ras Proteins

Share to Surveys and Questionnaires

Source

Identifiers

PMID: 41655752
DOI: 10.1016/j.critrevonc.2026.105176

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The RAS testing in real world management of metastatic colorectal cancer: The results of Italian Laboratories Survey.PMID 41655752Read ↗

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.Semantic proximity Read ↗

RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres.Semantic proximity Read ↗

Guideline-recommended incorporation of biomarker testing results in metastatic colorectal cancer therapy.Semantic proximity Read ↗

Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database.Semantic proximity Read ↗

How the lab is changing our view of colorectal cancer.Semantic proximity Read ↗

Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey.Semantic proximity Read ↗

RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers.Semantic proximity Read ↗

External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer.Semantic proximity Read ↗

Outcomes of Broader Genomic Profiling in Metastatic Colorectal Cancer: a Portuguese Cohort StudySemantic proximity Read ↗

Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach.Semantic proximity Read ↗

Tumor profiling of KRAS, BRAF, and NRAS gene mutations in patients with colorectal cancer: A Lebanese major center cohort study.Semantic proximity Read ↗

Real-Life Distribution of KRAS and NRAS Mutations in Metastatic Colorectal Carcinoma from French Routine Genotyping.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.